JamesHMcKerrowMD
Pathology • San Francisco, CAAnatomic Pathology, Clinical Pathology
Professor, Pathology, UCSF School of Medicine
Are you Dr. McKerrow?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 29 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
350 Parnassus Ave
San Francisco, CA 94117Phone+1 415-476-2960Fax+1 415-502-8193
Summary
- Dr. James McKerrow, MD is a board certified pathologist in San Francisco, California. He is currently licensed to practice medicine in California. He is affiliated with UCSF Medical Center and is a Professor at UCSF School of Medicine.
Education & Training
University of California (San Francisco)Residency, Pathology-Anatomic and Clinical, 1977 - 1978
Stony Brook Medicine/University HospitalInternship, Internal Medicine, 1976 - 1977
Stony Brook University Health Sciences Center School of MedicineClass of 1976
Certifications & Licensure
CA State Medical License 1977 - 2026- American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- 31 citationsAnalysis of cDNA encoding the hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) of Schistosoma mansoni; a putative target for chemotherapySydney P. Craig, James H. McKerrow, George Newport, Ching C. Wang
Nucleic Acids Research. 1988-07-25 - 21 citationsAcanthamoeba Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs.Brian Shing, Mina Balen, James H. McKerrow, Anjan Debnath
Expert Review of Anti-Infective Therapy. 2021-05-19 - 288 citationsIL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β IndependentMallika Kaviratne, Matthias Hesse, Mary Leusink, Allen W. Cheever, Stephen Davies
Journal of Immunology. 2004-09-15
Press Mentions
Experimental Therapy for Parasitic Heart Disease – K777 – May Also Help Stop COVID-19April 6th, 2021- Selva Raises $3m to Develop Novel Antiviral Against Covid-19August 12th, 2020
- Broad Spectrum Antiviral Oral Therapy Demonstrates High Potency Against COVID-19 in in Vitro Triggering Investor Demand to Fund Series A Round in Selva TherapeuticsJuly 21st, 2020
- Join now to see all
Grant Support
- LEAD Identification To Clinical Candidate Selection: Drugs For Chagas DiseaseNational Institute Of Allergy And Infectious Diseases2010–2011
- Hydrolysis Of Hemoglobin By Schistsoma Mansoni Cathepsin B-Like CysteineproteaseNational Center For Research Resources2010–2011
- Proteomics Analysis Of Schistosome Host-Invasion And MetabolismNational Center For Research Resources2005–2011
- Giardia Lamblia Cysteine Proteases: Trafficking, Localization, And FunctionNational Center For Research Resources2005–2011
- Structure Based Drug Design For Treatment Of Parasitic And Viral DiseasesNational Center For Research Resources2004–2011
- Mechanism Of Host Invasion By SchistosomesNational Center For Research Resources2004–2011
- Hydrolysis Of Hemoglobin By Schistsoma Mansoni Cathepsin B-Like Cysteine ProteaNational Center For Research Resources2005–2009
- Targeting Cysteine Proteases: Antiparasitic ChemotherapyNational Institute Of Allergy And Infectious Diseases2004–2008
- Parasitology And Cell BiologyNational Institute Of Allergy And Infectious Diseases2004–2008
- Host Protein Degradation By Schistosome ParasitesNational Institute Of Allergy And Infectious Diseases2003–2007
- High Throughput Assay For Screening Compounds(Rmi)National Institute Of Neurological Disorders And Stroke2005
- Predoctoral Training In Biomedical SciencesNational Institute Of General Medical Sciences2002–2005
- Hydrolysis Of Hemoglobin By Schistsoma Mansoni Cathepsin B-Like Cysteine ProteasNational Center For Research Resources2004
- Targeting Cysteine Proteases--Antiparasitic ChemotherapyNational Institute Of Allergy And Infectious Diseases1999–2003
- Core--Microscopy And Advanced Imaging FacilityNational Institute Of Diabetes And Digestive And Kidney Diseases2002
- Core--Inhibitor Screens, Cell Biology, And ParasitologyNational Institute Of Allergy And Infectious Diseases1999–2002
- Core--BiochemistryNational Cancer Institute1997–2002
- Serologic Marker Of Exposure To Schistosome ParasitesNational Center For Research Resources1998–2001
- Molecular Signals For Granuloma FormationNational Center For Research Resources1998–2001
- Cercarial Proteinase Of Schistosoma MansoniNational Center For Research Resources1998–2001
- Interdisciplinary Drug Design Targeting T Cruzi ProteaseNational Center For Research Resources1996–2001
- Proteases In Cancer: Biology &Drug DevelopmentNational Center For Research Resources1998–1999
- Serologic Marker Of Exposure To Schistosome ParasitesNational Institute Of Allergy And Infectious Diseases1997–1998
- Interdiscipilinary Drug Design Targeting A T CruziNational Institute Of Allergy And Infectious Diseases1995–1998
- Characterization Of Cercarial Proteinase Of S MansoniNational Center For Research Resources1997
- Cercarial Proteinase Of Schistosoma MansoniNational Institute Of Allergy And Infectious Diseases1993–1997
- Cysteine Proteases In FilariaeNational Center For Research Resources1996
- Characterization Of Cercariae Proteinase Of S MansoniNational Center For Research Resources1996
- Characterization Of Cercarial Proteinase Of S MansoniNational Institute Of Allergy And Infectious Diseases1990–1992
- Characterization Of Cercarial Proteinase Of S MansoniNational Institute Of Allergy And Infectious Diseases1987–1989
- Proteolytic Activity Of The Larvae Of S. MansoniNational Institute Of Allergy And Infectious Diseases1985
